Researchers at the University at Buffalo have engineered an injectable hydrogel that could transform how osteoarthritis (OA) is treated. Delivered as a liquid via a minimally invasive injection, the formulation converts into a smooth, lubricating semisolid depot at body temperature — acting as a long-lasting drug reservoir inside the joint for several weeks.

The platform pairs a biocompatible polymer matrix with drug-loaded nanocarriers capable of carrying high concentrations of poorly soluble (hydrophobic) compounds — a class of drugs that's historically difficult to deliver effectively. Medication is released gradually through diffusion, providing sustained local exposure while minimizing systemic side effects. Researchers validated the approach using a SIRT6 activator, and the system can be adapted for other disease-modifying compounds.

Key Takeaways:

• The hydrogel serves a dual purpose: sustained drug release and joint lubrication (viscosupplementation)
• It targets disease-modifying pathways — including chronic inflammation and cellular senescence — not just pain relief
• Potential applications extend beyond knee OA to post-traumatic OA, intervertebral disc degeneration, and rotator cuff degeneration
• Materials with prior regulatory acceptance were used, easing the path to clinical translation

Why it matters: Current intra-articular treatments wear off quickly and rarely slow disease progression. This platform could meaningfully reduce injection frequency, improve patient adherence, and open the door to delivering disease-modifying therapies directly where they're needed most.